Skip to main content
. 2014 Jun 6;2(5):695–700. doi: 10.3892/mco.2014.307

Table I.

Clinical characteristic of the 46 T-NHL patients.

No. Gender Age (yrs) Type Stage Primary or recurrence Group Combined with Cycles CAa PFS (mo) OS (mo)
1 M 45 NK/T I Primary TLD CHOPb+RTc 6 CR >42 >42
2 M 42 NK/T I Primary TLD CHOPb+RTc 6 CR >33 >33
3 F 40 ALCL I Primary TLD CHOPb 6 CR >32 >32
4 F 51 NK/T II Recurrence TLD DICEd 4 PD 3 5
5 M 77 AITL II Primary TLD COPe 4 PR 3 7
6 M 33 PTCL III Recurrence TLD CHOPb+RTc 4 PR 2 >5
7 M 70 AITL III Primary TLD CHOPb 4 PR 5 >12
8 M 41 NK/T I Primary TLD CHOPb+Gem+RTc 6 CR >26 >26
9 M 45 PTCL II Recurrence TLD CHOPb 3 CR >15 >15
10 M 53 T-LBL IV Recurrence TLD FMDf 2 PR 7.5 11.5
11 M 75 AITL IV Primary TLD CHOPb 2 SD 4 7
12 M 39 PTCL IV Primary TLD CHOPb+DDP+RTc 7 PR 9 21
13 F 32 SPTCL I Primary TLD CHOPb+DDP+RTc 6 CR >21 >21
14 M 71 NK/T IV Recurrence TLD CHOPb+GEM 5 CR 19 >21
15 F 50 AITL IV Primary TLD CHOPb+GEM 5 CR >18 >18
16 M 48 NK/T IV Recurrence TLD GEM+L-OHP 7 CR >16 >16
17 F 73 C-ALCL IIIE Recurrence TLD CHOPb 2 PD 1 >8
18 F 54 ALCL III Recurrence TLD DICEd 4 PR 12 >14
19 F 58 NK/T III Primary TLD CHOPb+RTc 2 CR >13 >13
20 F 74 NK/T IV Primary TLD GEM+L-OHP 2 PD 2 3
21 F 60 NK/T I Primary TLD GEM+L-OHP+RTc 4 CR >12 >12
22 M 45 NK/T I Primary TLD GEM+L-OHP 2 PD 1 3
23 M 56 NK/T II Primary TLD CHOPb+RTc 2 PR 3 3
24 F 60 NK/T I Primary TLD GEM+L-OHP+RTc 3 CR >8 >8
25 M 23 PTCL IV Primary Control CHOPb 2 PD 2 4
26 M 47 NK/T I Primary Control CHOPb+RTc 6 CR >37 >37
27 M 60 PTCL III Primary Control CHOPb 6 CR >36 >36
28 F 40 PTCL IV Primary Control CHOPb+GEM 5 PR 6 10
29 M 72 ALCL IV Primary Control CHOPb+RTc 6 SD 6 8
30 M 58 PTCL III Primary Control CHOPb 2 PR >3 >3
31 F 35 NK/T II Primary Control CHOPb 2 PD 0 3
32 M 37 NK/T I Primary Control CHOPb+RTc 4 CR >34 >34
33 M 29 ALCL III Recurrence Control CHOPb+RTc 6 SD 6 >11
34 M 65 ATCL IV Recurrence Control GEM+L-OHP 3 SD 5 7
35 M 65 NK/T II Primary Control CHOPb 2 PR 5 6
36 M 58 NK/T I Primary Control CHOPb+RTc 2 PR 2 8
37 M 38 NK/T I Primary Control GPh+DXM 2 PD 2 4
38 F 62 PTCL I Primary Control CHOPb+RTc 6 CR >26 >26
39 M 61 NK/T I Primary Control CHOPb+RTc 6 CR >23 >23
40 M 40 NK/T II Primary Control CHOPb 6 CR >21 >21
41 M 69 PTCL IV Primary Control CHOPb 8 CR 11 17
42 M 65 ALCL III primary Control CHOPb 2 PD 1 3
43 M 18 ALCL IV Primary Control CHOPb 2 PR 1 >6
44 M 65 ALCL III Primary Control CHOPb 2 PD 1 3
45 F 68 T-LBL I Primary Control CHOPb 4 PR 15 >15
46 M 36 NK/T II Primary Control EPg 5 CR >7 >7
a

Clinical assessment.

b

Cyclophosphamide, adriamycin, vincristine and prednisone.

c

Local radiotherapy.

d

Dexamethasone, ifosfamide, cisplatin and etoposide.

e

Cyclophosphamide, vincristine and prednisone.

f

Fludarabine, mitoxantrone and dexamethasone.

g

Etoposide and cisplatin.

h

Gemcitabine and cisplatin.

T-NHL, T-cell non-Hodgkin’s lymphoma; PFS, progression-free survival; OS, overall survival; M, male; F, female; NK/T, natural killer/T-cell lymphoma; ALCL, anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; PTCL, peripheral T-cell lymphoma; T-LBL, precursor T-lymphoblastic lymphoma; SPTCL, subcutaneous panniculitis-like T-cell lymphoma; C-ALCL, primary cutaneous anaplastic large-cell lymphoma; ATCL, adult T-cell leukemia/lymphoma; TLD, thalidomide; GEM, gemcitabine; L-OHP, oxaliplatin; DXM, dextromethorphan; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.